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Clinical Investigations

Outpatient versus observation/inpatient
management of emergency department
patients rapidly ruled-out for acute myocardial
infarction: Findings from the HIGH-US study
Richard M. Nowak, MD a ,,1 Gordon Jacobsen, MS b , Alexander Limkakeng Jr, MD c , William F. Peacock, MD d ,
Robert H. Christenson, PhD e , James McCord, MD f , Fred S. Apple, PhD g , Adam J Singer, MD h , and
Christopher R. deFilippi, MD i ,1 Detroit, MI; Durham, NC; Houston, TX; Baltimore, MD; Minneapolis, MN; New
York, NY; Falls Church, VA

Background

The actual Emergency Department (ED) dispositions of patients enrolled in observational studies and
meeting criteria for rapid acute myocardial infarction (AMI) rule-out are unknown. Additionally, their presenting clinical
proﬁles, cardiac testing/treatments received, and outcomes have not been reported.

Methods

Patients in the HIGH-US study (29 sites) that ruled-out for AMI using a high-sensitivity cardiac troponin I 0/1hour algorithm were evaluated. Clinical characteristics of patients having ED discharge were compared to patients placed in
observation or hospital admitted (OBS/ADM). Reports of any OBS/ADM cardiac stress test (CST), cardiac catheterization
(Cath) and coronary revascularization were reviewed. One year AMI/death and major adverse cardiovascular event rates
were determined.

Results

Of the 1,020 ruled-out AMI patients 584 (57.3%) had ED discharge. The remaining 436 (42.7%) were placed in
OBS/ADM. Patients with risk factors for AMI, including personal or family history of coronar y arter y disease, hypertension,
previous stroke or abnormal ECG were more often placed in OBS/ADM. 175 (40.1%) had a CST. Of these 32 (18.3%) were
abnormal and 143 (81.7%) normal. Cath was done in 11 (34.3%) of those with abnormal and 13 (9.1%) with normal CST.
Of those without an initial CST 85 (32.6%) had Cath. Overall, revascularizations were performed in 26 (6.0%) patients.
One-year AMI/death rates were low/similar (P = .553) for the groups studied.

Conclusions

Rapidly ruled-out for AMI ED patients having a higher clinician perceived risk for new or worsening
coronar y arter y disease and placed in OBS/ADM underwent many diagnostic tests, were infrequently revascularized and
had excellent outcomes. Alternate efﬁcient strategies for these patients are needed. (Am Heart J 2021;231:6–17.)
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There have been algorithms published detailing the
use of high sensitivity cardiac troponin (hs-cTn) measurements for the rapid rule-out of acute myocardial
infarction (AMI) in Europe1 , 2 and more recently in the
United States (US).3-5 These reports indicate that many
(40%-60%) of the patients presenting to the Emergency
Department (ED) with symptoms suspicious for AMI
can have this diagnosis ruled out using a single very
low baseline hs-cTn level or the combination of a low
baseline measurement and a small hs-cTn delta change
1 hour later. While it is reported that these patients
can be rapidly discharged from the ED there are no
data available that documents outcomes based on the
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initial physician determined dispositions in different EDs
in the US. Additionally, it is not known what clinical
factors might be associated with emergency physicians
decisions to directly ED discharge patients that have
been placed in the AMI ruled out zone of the newer
hs-cTn algorithms, rather than place them in observation
or inpatient beds (OBS/ADM) in order to determine
the presence and severity of any undiagnosed coronary
artery disease (CAD) or the worsening of any preexisting
CAD and how to best manage these patients.
In the High Sensitivity Cardiac Troponin I in the United
States (HIGH-US) study5 the use of a high sensitivity cardiac troponin I (hs-cTnI) rapid (0/1-hour) evaluation algorithm (using specific hs-cTnI cut points previously reported in a western European population6 ) ruled-out for
AMI in 1,065 (50.4%) patients presenting to the ED with
symptoms suspicious for AMI. The overall negative predictive value (NPV) was 99.7% (95% confidence interval [CI], 99.2%-99.9%) and sensitivity was 98.7% (95%
CI, 96.3%-99.6%). The overall 30-day risk of post discharge AMI/death in these patients was very low (0.2%).
Other studies have also reported and validated that patients with symptoms suggestive of AMI who have low
initial and small absolute changes in high sensitivity cardiac troponin (hs-cTn) values with serial sampling (overall 56.6% of all patients evaluated for AMI) had similarly
high NPVs (99.5%) for AMI and low 30-day rates (0.2%)
for AMI/death.7
It has been reported that by using these rapidly ruled
out AMI hs-cTnI algorithms these patients can have
a rapid ED discharge, thus decreasing their length of
stay (LOS) in the ED. However, given that the excellent reported outcomes are typically based on observational data that incorporates physician triage and testing decisions, a better understanding of factors that
are associated with these decisions remain important
to quantify before accepting that a rapid rule-out of
AMI with an hs-cTn assay should result in a speedy ED
discharge.
Therefore, the objectives of this report were to: (1)
determine the proportion of ED dispositions (ED discharge versus OBS/ADM placement) in the subgroup of
HIGH-US study patients meeting the AMI ruled out criteria using the hs-cTnI 0/1-hour algorithm (“ruled out
patients”) but who were managed clinically using standard of care conventional troponin assays that were the
only cTn results available to the clinicians; (2) compare
their various clinical presentations and profiles based on
their dispositions; (3) explore the cardiac evaluations
and treatments received in patients placed in OBS/ADM,
and (4) to report separately for each group their 1-year
AMI/all cause death and major adverse cardiovascular
event (MACE) rates. MACE, for our study, was defined
as the patient having an AMI, all cause death, a revascularization procedure or developed congestive heart
failure.
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Methods
Funding sources
The HIGH-US study was supported and funded by
Siemens Healthcare Diagnostics Inc., 511 Benedict Avenue, Tarrytown, NY 10,591, USA. The authors are solely
responsible for the design and conduct of this multicenter study, all study analyses, the drafting and editing of all
the resulting submitted/published manuscripts and their
final contents.
Study design and setting
The HIGH-US Food and Drug Administration (FDA)
510k study prospectively enrolled adults’ ≥22 years of
age who presented to the ED with any suspicion for AMI
prompting the clinical ordering of a contemporary cTn
test. The treating ED physicians were not aware of the
study hs-cTnI measurements at the time that they evaluated the patient as these were batch analyzed later, after patient enrollment was completed. Written informed
consent was obtained from all patients enrolled. The EDs
consisted of 29 centers in 16 different states across the
US, including both tertiary urban and suburban community hospitals. There were no patient exclusion criteria.
Given the requirement for obtaining consent before enrollment generally, but not always, took place during the
weekdays and so was a convenience trial. The protocol
was approved by either a central or local institutional review board and enrollment occurred between April 2015
and April 2016. All enrolled patients were clinically managed by the treating physicians which included the use of
contemporary FDA cleared troponin measurements and
any specific institutional guidelines or protocols. Additionally, a HEART score was later calculated for each patient (research coordinators obtained the level of clinical
suspicion as being low, moderate or high for AMI from
the treating ED physician).8
Blood sample collection protocol and testing
The time points for study sample collection for analysis
included a baseline (≤90 minutes from the first clinical
blood collection) and a 1 hour (60 ± 15 minutes) later
draw. Samples were collected in lithium heparin and
serum blood tubes and sent to one of the following
laboratories for testing (Siemens Healthcare Diagnostics,
Tarrytown, NY; Research & Development Institute,
Calabasas, CA; Baylor Scott & White Healthcare Texas
A&M Health Science Center, Temple, TX; University of
Maryland, Baltimore, MD; Minneapolis Medical Research
Foundation, Minneapolis, MN) where measurements for
hs-cTnI were performed on the Atellica IM Analyzer and
ADVIA Centaur XP system. The Atellica IM hs-cTn assay
is a 3-site sandwich immunoassay that uses direct chemiluminescent technology and has a measuring range of
2.5 to 25,000 ng/L, a limit of detection of 1.6 ng/L and
limit of quantitation of 2.5 ng/L (20% coefficient of
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variation) and a combined sex 99th percentile upper
reference limit (URL) of 47 ng/L.9 Hs-cTnI measurements
run on the Atellica and ADVIA Centaur devices were
similar and have been previously reported.5
Further details of the HIGH-US trial design including additional sample collections, sample types, preanalytical handling, and testing have been previously
published.10 , 11
For patients placed in OBS/ADM all cardiac stress test
(CST) reports were reviewed and entered in the database
as being either normal or abnormal (indeterminate results were considered abnormal). Additionally, any coronary catheterization (Cath) and coronary revascularization procedure reports for these patients were additionally reviewed. Cath results were also entered into the
database as being normal or abnormal. An abnormal Cath
finding was defined as a report containing at least one
quantitative stenosis ≥50% in at least one coronary artery
or major branch.

AMI diagnosis adjudication
Patients clinical characteristics, ECGs, all lab values
including site specific contemporary troponin measurements (each site specific assay and its 99th% value were
made available), other diagnostic or therapeutic cardiovascular procedures, final patient disposition (ED discharge, observation placement or hospital admission)
and all clinical information available during the 30 days
after ED presentation were made available to each physician adjudicator. This included any initial narrative and
discharge summary with redaction of any final hospital
AMI diagnosis. At the time of this study standard of care
guidelines in the US and Europe recommended a baseline and a 3- to 6-hour conventional troponin value for
the evaluation of patients with symptoms suspicious for
AMI. During study enrollment no FDA approved hs-cTn
assays were available for clinical use.
The adjudication panel consisted of cardiologists and
ED physicians with 5 physicians (at least 2 members of
each specialty) assigned to each case. These individuals and the treating EM physicians were blinded to the
hs-cTnI results. Adjudicators determined AMI diagnosis
(type 1 or type 2) using the Third Universal Definition of
Myocardial Infarction.12 No relative or absolute threshold
was prespecified for a significant rise and/or fall of cTn
levels. Final diagnosis was determined by the majority
adjudicator opinion.
Follow-up for adverse cardiovascular outcomes
AMI/death and MACE outcomes were recorded for up
to 1 year. This information was collected by review of
the patients’ institutional medical records or phone call
with the patient or their relative/friend or by contacting
their primary care physician or cardiologist. Patients also
returned for 1 year in person visit (which included an
ECG). Death status was obtained by review of publicly

available information which included the Social Security
Death Index and obituary searches (if all other methods
failed).

Primary data analysis
The clinical characteristics of patients with an ED discharge versus an OBS/ADM were compared using medians with interquartile ranges for continuous data and
percentages with 95% CIs for categorical data. Stepwise logistic regression modeling was used to determine
which study characteristics were significantly associated
with an ED discharge versus an OBS/ADM placement.
Kaplan-Meir curves were obtained to display the probability of AMI/death and MACE during the first year of
follow-up for the ED discharged and OBS/ADM patients.
The Kaplan-Meier curves were compared using the logrank survival test. Lastly the overall ED discharged versus OBS/ASDM disposition rates and the CST and/or
Cath/revascularization utilizations in the OBS/ADM patients were described across the participating medical
centers. All analysis was performed using SAS version
9.4.

Results
Dispositions for AMI ruled out patients
A total of 2,505 patients were enrolled in the HIGHUS Study and 2,113 qualified for the assessment of the
hs-cTnI 0/1-hour AMI rule-out algorithm. Of these 2,037
had a recorded final disposition other than signed out
against medical advice (76 subjects). Additionally 15 patients were adjudicated as having a ST-segment elevation AMI and were excluded from the analyses, leaving 2,022 for the population studied. Of these 1,020
(50.4%) met the AMI ruled out criteria using the hs-cTnI
0/1-hour algorithm values (67% with a baseline hs-cTnI
<3 ng/L and 33% with a baseline <6 ng/L and a delta
baseline 1 hour change of <3 ng/L5 ). Five hundred and
eight four (57.3%) patients had an ED discharge and 436
(42.7%) were placed in OBS/ADM. The frequency of patients having an ED discharge rather than being placed in
OBS/ADM varied significantly (0.0%-94.1%) among 27 (2
centers had no patients eligible for analysis, 1 enrolled 2,
the other 5 patients) of the medical centers (Figure 1). In
most EDs most placed in the hs-cTnI AMI ruled-out zone
patients had an ED discharge, while in a few centers most
were placed in OBS/ADM.
Patient clinical characteristics
A comparison of the clinical characteristics and initial ECG findings of patients with an ED discharge versus OBS/ADM disposition are shown in Table I. Patients
placed in OBS/ADM were older and had more traditional risk factors for AMI including a personal history
of CAD, a family history of CAD, stroke and no heart
failure (HF) hospitalization with worse renal function
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Figure 1

Dispositions of AMI ruled out patients by participating medical center. AMI, acute myocardial infarction.

and with fewer having a normal ECG. The HEART score
was overall lower in ED discharged patients compared
to those placed in OBS/ADMI (median 3.0, interquartile
range [IQR] 3.0-4.0 versus 4.0, IQR 3.0-5.0 respectively)
and more often low (0-3) and less often moderate (4-6) or
high (>7) when divided into specific ranges. The higher
of the baseline and 1-hour hs-cTnI values in each group
were very low but different in the ED discharged (median 2.0 ng/L, IQR 1.1-3.5) and OBS/ADM (median 2.9
ng/L, IQR 1.8-4.3) groups. No patients with an ED discharge had an adjudicated AMI final diagnosis while 3
(0.7%) of those placed in OBS/ADM hs-cTnI algorithm
zone did. In these 3 patients at least 1 of the contemporary troponins was >99th percentile in the ED while the
hs-cTnI results were not. Why at least one of the contemporary troponin results was above the 99th percentile
while none of a serial hs-cTnI results in these 3 patients
is not clear. Two were admitted to the hospital (1 had
an adjudicated type 1, another a type 2 AMI) while the

third patient was seen by cardiology in the ED and after a cardiac stress test was performed had an ED discharge A multivariate logistic regression analysis of the
clinical parameters in Table I was performed. The significant factors associated with being placed in OBS/ADM
are shown in Table II. These included a personal history
of CAD, a family history of CAD, history of hypertension,
previous stroke, no history of HF hospitalization or the
patient had an abnormal ECG.

Patient evaluations, treatments and outcomes
ED discharged patients had a shorter hospital LOS (median 12 hours, IQR 12-12) than those patients placed in
OBS/ADM (median 24 hours, IQR 24-48).
No deaths or AMIs occurred in the 436 patients rapidly
ruled-out for AMI while they were in the hospital.
Around 175 (40.1%) of OBS/ADM patients received
a CST. The types of CST performed were 24 (13.7%)
had exercise stress testing without imaging, 82 (46.9%)
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Table I. Characteristics of AMI ruled out patients by ﬁnal disposition
Patient characteristics

ED Discharge (n = 584)

Age, median (IQR), y
Male sex, percent (95% CI)
Race, percent (95% CI) White
Black
Other or Multiple
Hispanic or Latino, percent (95% CI)
Symptom onset to ﬁrst blood draw, median (IQR), h
First draw within 3 h of onset, percent (95% CI) h
AMI risk factors, percent (95% CI)
Hypertension
Dyslipidemia
Diabetes mellitus
Current smoker
Former smoker
Never smoked
Coronar y arter y disease
Previous myocardial infarction
Previous coronary revascularization
Peripheral artery disease
Previous stroke
Renal dialysis
Heart failure hospitalizations
Family history of coronary artery disease
CKD-EPI eGFR <60 mL/min per 3.73 m²
Creatinine, median (IQR), mg/dL
Body mass index, median (IQR), kg/m2
ECG ﬁndings, percent (95% CI)
Left bundle branch block
ST-segment depression ≥0.5 mm
T-Wave inversion
Normal ECG
HEART score (95% CI)
0–3
4–6
>7
AMI ﬁnal diagnosis

52.0 (44.0-59.0)
43.8 (39.8-48.0)
59.8 (55.7-63.8)
36.5 (32.6-40.5)
3.8 (2.4-5.7)
9.6 (7.3-12.3)
6.9 (3.4-25.7)
19.3 (16.2-22.8)

Observation/hospital discharge
(n = 436)
55.0 (49.0-62.5)
49.3 (44.5-54.1)
63.3 (58.6-67.8)
33.5 (29.1-38.1)
3.2 (1.8-5.3)
6.7 (4.5-9.5)
7.8 (3.6-25.6)
16.5 (13.1-20.3)

50.4 (46.3-54.6)
27.9 (24.2-31.8)
19.1 (16.0-22.5)
26.5 (23.0-30.3)
22.9 (19.6-26.6)
50.5 (46.4-54.6)
16.1 (13.1-19.3)
7.2 (5.2-9.6)
10.5 (8.1-13.4)
1.4 (0.6-2.8)
4.0 (2.6-6.0)
0.2 (0.0-1.0)
7.0 (5.0-9.4)
42.8 (38.5-47.1)
5.7 (4.0-8.0)
0.8 (0.7-1.0)
29.7 (25.9-34.6)

71.8 (67.3 – 76.0)
45.3 (40.4 – 50.2)
30.0 (25.7 – 34.5)
26.4 (22.3-30.8)
32.3 (28.0-37.0)
41.3 (36.6-46.1)
41.0 (36.3-45.8)
23.0 (19.1-27.4)
31.1 (26.7-35.8)
3.0 (1.6-5.2)
13.7 (10.5-17.4)
0.0 (0 0-0.9)
11.4 (8.5-14.8)
52.8 (47.8-57.8)
9.7 (7.0-12.8)
0.9 (0.7-1.0)
30.4 (26.4-35.2)

0.5 (0.1-1.5)
2.1 (1.1-3.6)
3.8 (2.4-5.7)
51.7 (47.6-55.8)

0.9 (0.2-2.3)
3.0 (1.6-5.1)
6.2 (4.1-8.9)
36.5 (31.9-41.2)

7070.5 (66.5-74.2)
66.5 29.2 (25.4-33.1)
0.4 (0.0-1.3))
0.0 (0.0-0.6)

35.0 (30.4-39.7)
063.8 (59.1-68.4)
1.2 (0.4-2.7)
0.7 (0.1-2.0)

AMI, acute myocardial infarction; CI, conﬁdence interval; Categorical data is given as Frequency (Percent of Total) and numerical data is given as Median (Interquartile
Range).

Table II. Clinical variables associated with an
observation/inpatient disposition for AMI ruled out patients
Variable
History of coronary
artery disease
History of previous stroke
No prior heart failure
hospitalization
History of hypertension
Abnormal ECG
Family history of
coronar y arter y
disease

Odds ratio
estimate

Odds ratio 95%
conﬁdence limits

2.940

1.999

4.325

2.742
2.022

1.460
1.121

5.148
3.647

1.895
1.766
1.399

1.361
1.292
1.024

2.638
2.413
1.912

nuclear myocardial imaging perfusion with pharmacologic stressor, 32 (18.3%) nuclear myocardial imaging
perfusion with exercise stressor, 13 (7.4%) echocardio-

graphy with pharmacologic stressing, and 25 (1.4%)
echocardiology with exercise stress testing.
Thirty-two (18.3%) CSTs were abnormal and 143
(81.7%) normal. For patients who had a CST Cath was
done in 11 (34.3%) of those with abnormal and 13 (9.1%)
of patients with a normal CST result. Of those without an initial CST, 85 (32.6%) had Cath and of these 47
(55.3%) were abnormal. Overall, Cath was completed in
109 (23.6%) and revascularization was performed in 26
(6.0%) patients (25 percutaneous coronary interventions
and 1 coronary artery bypass surgery). A consort diagram
detailing the overall cardiac testing and resulting therapeutic interventions for the OBS/ADM patients is shown
in Figure 2. In these patients there did not appear to be
any uniform approach to the ordering of CSTs and specific medical actions, including Cath, if the CSTs were
reported as being normal or abnormal.
The frequency of cardiac testing (no CST, CST only,
Cath only, both CST and Cath) for patients with
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Figure 2

Cardiac evaluations and interventions for patients placed in OBS/ADM.

OBS/ADM placement was different when compared
across the 27 participating medical centers for this analysis (Figure 3).
The 1 year AMI/death rates were very low for both
groups (2.4% for ED discharged, 2.9% for OBS/ADM) and
were not significantly different (P = .553) between the
groups (Figure 4). At 1-year after ED presentation there
were 3 AMIs and 9 deaths in the ED discharged patients
and 7 AMIs and 6 deaths in those placed in OBS/ADM.
The first AMI and deaths occurred at 69 and 7 days and
in 40 and 21 days respectively after enrollment in the
ED discharge and OBS/ADM groups. The 1 year MACE
rates were higher in both groups (5.9% for ED discharge,
18.5% for OBS/ADM) and were significantly different (P
< .001) between the 2 groups (Figure 5).

Discussion
We have previously reported from the HIGH-US study
that many ED patients presenting with symptoms suspi-

cious for AMI can be rapidly ruled out using a 0/1-hour
hs-cTnI algorithm.5 We detail in this report the clinical
characteristics, dispositions, further assessments and
interventions for 1,022 of these individuals who were
rapidly ruled-out using the 0/1 hs-cTnI algorithm and
compared their clinically determined ED dispositions
during the study period. There are several important
findings. First, ED disposition of these patients was quite
different among the participating medical centers, perhaps based on the population served, the different local
troponin assays or use of various institution protocols.
Second, there were differences in the clinical characteristics between ED discharged patients compared to
those placed in OBS/ADM. The latter were older and
had more traditional risk factors for AMI. Third, despite
having more of these risk factors and comorbities the
OBS/ADM patients had similarly low AMI/death adverse
outcomes 365 days after ED enrollment. The OBS/ADM
patients had many noninvasive and invasive procedures
ordered and completed but this ultimately resulted in
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Figure 3

Cardiac testing in the AMI ruled out patients by participating medical center. AMI, acute myocardial infarction.

relatively few revascularizations procedures performed
during their hospital stays. Which, if any, further cardiac
testing/treatments the ED discharged patients had on an
outpatient basis was not collected in the HIGH-US study.
ED physicians, when evaluating patients for possible
AMI, often use an accepted risk stratification score such
as the HEART score13 and/or their own clinical judgment to decide which patients ruled out for AMI using
troponin measurements can have an ED discharge and
which others require further evaluations in OBS/ADM.
Our reported HEART scores were independently calculated after research personal determined if the treating
physician thought that the presenting symptoms were
of low, moderate or high suspicion for AMI. We do not
know if, or to what extent, a treating ED physician determined HEART score might have played in their ED disposition decision making during the study period. Consistent with having increased traditional cardiac risk factors for AMI those patients rapidly ruled out for AMI
patients placed in OBS/ADM had higher overall HEART

scores with more patients having scores in the 4 to 6 and
>7 range as compared to those with an ED discharge.
However, as shown in Table I, about one-third of patients
with an ED discharge and two-thirds of those placed in
OBS/ADM had a HEART score of ≥4, suggesting that the
score alone was not well associated with determining ED
dispositions.
The clinical parameters independently most associated
with the decision to place patients in OBS/ADM were a
personal history of CAD, a family history of CAD, a history of hypertension, prior stroke, no hospitalization for
HF, and the patient having an abnormal ECG. The odds
ratios for both prior revascularization and prior MI did
not encompass 1.0 (but indicated that a patient had a
personal history of CAD) and so were not included in
Table II. It is not clear why the variable “no history of HF
hospitalization” was associated with a decision to place
a patient in OBS/ADM. This may have been a random result given the number of parameters placed in the regression analysis or that patients with prior admissions for
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Figure 4

One-year Kaplan-Meir plots for AMI/death in AMI ruled out patients having EDD versus OBS/ADM placement (P= .553). AMI, acute
myocardial infarction.

HF often have chronically elevated troponins and thus
are adjudicated as having chronic cardiac injury. If patients did not have any elevated contemporary troponin
value, then the ED clinicians may have chosen to place
the patient in OBS/ADM to have further cardiac testing
completed. Many of the 436 OBS/ADM AMI ruled out
patients underwent further evaluations to determine the
presence and severity of CAD or its progression if already
known to be present and what should be done regarding
its management. Our study demonstrates, like previous
ones,14 that traditional risk factors for AMI contribute
very little to prognosis above and beyond high sensitivity cardiac troponin values when rapidly ruled out for
AMI patients are being evaluated in the ED. We also report that in study patients with very low hs-cTnI measurements a calculated HEART score was not useful for
predicting clinical outcomes.
Additional cardiac stress testing among these 436 AMI
ruled out patients placed in OBS/ADM was quite fre-

quent. Overall only 26 (6.0%) patients received a cardiac
revascularization procedure, not because a new AMI diagnosis had been made, but rather because the treating
ED clinicians thought that there might be further cardiac
testing needed to detect new underlying CAD or they
were suspicious that any preexisting CAD might have
progressed and these concerns might require urgent invasive intervention to prevent future adverse outcomes
and/or to potentially treat ongoing symptoms. There was
significant heterogeneity between participating sites regarding the use of further cardiac diagnostic testing and
the choice of an initial noninvasive or invasive strategy
for treatment of CAD, perhaps based on different institution protocols or individual practitioners’ practice patterns.
We have previously reported that the overall 30-day
AMI/death rates for rapidly ruled out AMI patients were
very low (0.2%) and now report that these adverse outcomes at 1 year in the ED discharged and OBS/ADM
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Figure 5

One-year Kaplan-Meir plots for MACE in AMI ruled out AMI patients having ED Disch versus OBS/ADM placement (P < .001). AMI, acute
myocardial infarction; ED, emergency department; MACE, major adverse cardiovascular event.

placed individuals were also low (2.4% and 2.9%, respectively) and not significantly different. In a large multicenter European study of 4,368 patients rapidly ruled out for
AMI using hs-cTn algorithms using hs-cTn values in the
rule-out zones overall (there was no reporting of ED patient dispositions) there were similarly very low 30-day
and low 1-year AMI/all cause death rates reported (0.5%
and 1.7% for hs-cTnT, respectively and 0.6% and 2.1% for
hs-cTnI, respectively (15 , online data).
A recent US study of 79,040 patients who were ruled
out for acute coronary syndrome (AMI and unstable
angina) in the ED, of which 16,164 (20.5%) received
noninvasive cardiac testing (NIT) within 72 hours of the
ED visit, there was minimal improvement in absolute 30
day adverse outcomes (AMI/death) rates in these patients
when compared to those who did not receive NIT (both
groups <1%). Furthermore, to prevent 1 death or 1 AMI
in this 30-day period by using NIT within 72 hours of

the ED visit the number of patients needed to treat was
500 and 330 respectfully. The authors concluded that the
clinical strategy of early NIT after patients had been ruled
out for AMI in the ED may not be optimal for most of
these patients, given the large numbers needed to treat.16
These results support our hypothesis that ED patients
rapidly ruled out for AMI using hs-cTnI could be safely
ED discharged with close outpatient follow-up.
Our results raise 2 fundamental questions: (1) did the
26 revascularization procedures performed on an urgent
basis in the OBS/ADM in patients enrolled in the HIGHUS study contribute to their low death/AMI rates in the
ensuing 30 and 365-days after ED presentation and (2) if
not, what might be an alternative management plan for
this rapidly AMI ruled out by hs-cTnI patient population.
The recently reported results of the International Study
of Comparative Health Effectiveness with Medical and
invasive Approaches (ISCHEMIA) trial17 might help to
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answer these questions. This international study showed
that patients having stable and possibly cardiac related
symptoms with inducible moderate or severe cardiac ischemia during stress testing (ie, traditionally identifying
patients with significant CAD requiring invasive intervention) had no difference in death from cardiovascular causes, myocardial infarction, resuscitated cardiac arrest or hospitalization for unstable angina or heart failure
rates in the following 3.2 years whether they received
cardiac revascularization or optimal medical therapy
alone (taking medicines and making lifestyle changes)
and subsequent Cath if the medical therapy failed.18
An alternative treatment pathway might be to have the
patients without known CAD to first receive a coronary
tomographic coronary angiogram (CTCA) while in the
ED or after a follow-up visit as an outpatient, understanding that not all patients (those with arrythmias, chronic
or acute renal injury etc.) are candidates for CTCA. If
significant CAD is seen on the ED study and the patient’s symptoms are stable, then medical therapy for
CAD could be initiated and the patients might have an
ED discharge with close outpatient follow-up. Additionally, recent evidence suggests that plaque characterization that can be easily obtained in an automated manner may be particularly powerful for identifying stable
patients at highest risk for a subsequent AMI.19 For stable patients with known preexisting CAD but who have
ruled out for AMI using hs-cTnI further optimization of
medical therapy might be initiated and the patient discharged directly home, also with close outpatient followup
A strategy20 utilizing outpatient management of patients with stable chest pain with CTCA versus “usual
care” (including cardiac stress testing for possible CAD)
has been associated with a lower risk for AMI and cardiac
death over 5 years, likely driven by the initiation of more
preventative medical treatment and not more coronary
artery revascularizations.
The 1 year MACE rates were significantly higher in
the OBS/ADM patients when compared to the ED discharged group. The initial steep rise in the MACE outcomes in this rapidly AMI ruled-out group was because
the revascularization procedures performed while patients were in OBS/ADM were included in the MACE
analyses. Our results suggest that the revascularization
procedures urgently performed while patients were in
the hospital might have been replaced by initiating or
optimizing medical cardiovascular care and an early ED
discharge, with close outpatient follow-up. Additionally,
the OBS/ADM group had much more additional comorbidity and risk factors for AMI than the ED discharged
patients and this likely explains their continued higher
MACE rates over the ensuing 1 year. We believe that the
goals of a safe ED discharge for these rapidly AMI ruledout patients are low 30-day and 1-year AMI/death rates
while providing appropriate ED medical therapies and
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close follow-up. This strategy provides for careful control of patients’ comorbidities and any underlying CAD,
thus minimizing their MACE rates over the ensuing 365
days.
It has been recently reported that the use of rapid highsensitivity troponin assays to rapidly rule-out AMI and
thus to allow more patients to be discharged directly
from the ED rather than to be hospitalized for further
evaluations may not satisfy the medical care needs of patients, as they often may not know, and it is often not adequately discussed with them, what their future health
status could be.21 This emphasizes that the ED evaluation cannot be considered complete with an accelerated
AMI rule-out algorithm without a minimum of provider
reassurance or having further evaluations completed as
needed. If this is not done then significant ED recidivism
could result, potentially negating the benefit of the initial
rapid AMI rule-out evaluation using hs-cTn assays.

Limitations
One, we are unable to report a detailed cost effectiveness analysis of ED discharged versus OBS/ADM for
rapidly AMI ruled-out patients. However, the median LOS
was a day half longer in the OBS/ADM patients and the
costs of placing a patient in OBS/ADM, even for a relatively short time period, are higher. Given the chronic
overcrowding of EDs and hospitals (especially observation units) any increased number of early ED discharged
patients ruled-out for AMI would be helpful in providing
more efficient ED care. In addition, there were likely substantial additional costs incurred for the urgent 175 CSTs,
109 Cath studies and the 26 coronary revascularization
procedures performed that resulted after patients were
placed in OBS/ADM. Given the absence of a difference
in the adverse 1-year events between the 2 groups, combined with a recent understanding of limited efficacy of
coronary revascularization to reduce future AMI/death in
the absence of an AMI, it would be difficult to demonstrate meaningful cost-effectiveness for these additional
urgent evaluations and invasive treatments that were associated with the OBS/ADM approach in patients rapidly
ruled out for AMI using a hs-cTnI algorithm.
Two, if hs-cTnI and not a variety of contemporary troponin assays had been used to adjudicate for AMI diagnosis, the NPV and sensitivity of the ruled-out zone patients
and the PPV and number of ruled-in AMIs of the hs-cTnI
algorithm zone may have been different. The adjudicated
reclassification of AMI or cardiac injury using an hs-cTnI
value below the diagnostic threshold of a standard care
contemporary assay has been reported to occur in 17% of
patients.22 However, in that report there was no increase
in the primary outcome of AMI or cardiovascular death
within 1 year in those patients that had a reclassified AMI
diagnosis.
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Three, there was a possible time draw bias increasing
both the NPVs and the positive predictive values (PPVs)
in the study as the hs-cTnI specimens were draw approximately 40 minutes after the standard of care (SOC) blood
samples were obtained, as written informed consent was
required before any patient could be enrolled. Therefore,
the excellent prognosis seen in the AMI ruled-out patients’ needs to be considered in the context of this later
blood draw.
Four, patient enrollments were not consecutive in time
at any site and enrollment periods varied at each participating medical center. Whether the results might have
been different if consecutive patient enrollment was accomplished is not known.
Five, 5% of enrolled patients did not have an adequate
baseline blood sample drawn (no baseline hs-cTnI value),
potentially leading to a bias for patients where blood collection is challenging.
Six, for the ED discharged group we do not know if
any cardiac medications were prescribed at ED discharge
or later during the follow-up period nor do we know if
any outpatient cardiac testing was completed during this
time. These variables will require attention in future clinical study designs.
Lastly, this report is a retrospective post-hoc analysis
looking at the characteristics of patients meeting the
rule-out criteria of the rapid 0/1 h hs-cTnI algorithm.
The hs-cTnI algorithm was not used as part of the patient’s clinical care, including the decision for ED discharge versus OBD/ADM placement. The HIGH-US trial
did not have an interventional component to it.

Conclusions
Our observational findings from the HIGH-US multicenter study suggest that most patients presenting to the
ED with symptoms suspicious for AMI but meeting the
rapid rule-out AMI criteria using an hs-cTnI 0/1-hour algorithm might be managed as outpatients. There was wide
variation between medical centers for placing patients in
OBS/ADM and for any subsequent cardiovascular testing
that they received. We provide a quantifiable estimate of
the increased proportion of AMI ruled-out patients using hs-cTnI who might have an ED discharge, including
those with clinical cardiac risk factors traditionally felt
to be at higher risk for CAD. The very important issue
of how to optimally and consistently manage patients
rapidly ruled-out for AMI using the newer hs-cTnI algorithm requires further prospective clinical trials to validate our results and recommendations determined from
the HIGH-US study.
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